Actively Recruiting
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Led by Efferon JSC · Updated on 2025-06-05
60
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
CONDITIONS
Official Title
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of cardiogenic shock complicating acute myocardial infarction within 4 hours
- Stages B or C of cardiogenic shock according to SCAI
- Patient condition allows treatment with Efferon CT device for at least 4 hours
- SOFA score of 12 or less
You will not qualify if you...
- Broken-heart syndrome (takotsubo cardiomyopathy)
- Postcardiotomy cardiogenic shock
- Acute myocardial infarction within the last 4 weeks
- Myocarditis
- Cardiac trauma
- Charlson comorbidity index greater than 9 points
- Chronic kidney disease stage 5D requiring continuous hemodialysis
- Acute pulmonary embolism
- Acute cerebral circulatory collapse
- Transfusion reaction
- Use of immunosuppressive therapy for cancer or autoimmune diseases
- Pregnancy
- Any other clinical condition deemed by the investigator to exclude participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tomsk NRMC Cardiology Research Institute
Tomsk, Russia, 634012
Actively Recruiting
Research Team
A
Alexandr Shelehov-Kravchenko, PhD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here